Hypertrophic Cardiomyopathy, Sudden Death and Implantable Defibrillators
Downloads
Implantable cardiac defibrillators (ICD) are greatly efficient in eliminating arrhythmias in patients withhigh-risk hypertrophic cardiomyopathy, showing that this equipment has a contribution in the prevention and treatment of unexpected death. When patients have risk marker, unexpected death in one or more first-degree relations with maximal left ventricle wall thickness 30 mm of current and unexplained syncopal episode, ICD installation is considered appropriate. If one has a dangerously fast heartbeat that prevents heart from pumping enough blood to the rest of body ventricular fibrillationor ventricular tachycardia, or if the patient is at high risk of suffering such a heart rhythm problem (arrhythmia), usually due to a weak heart muscle, the patient can survive using ICD.
Maron, B. (2018). Clinical Course and Management of Hypertrophic Cardiomyopathy. New England Journal Of Medicine, 379(7), 655-668.
doi: 10.1056/nejmra1710575
Marian, A., &Braunwald, E. (2017). Hypertrophic Cardiomyopathy. Circulation Research, 121(7), 749-770. doi: 10.1161/circresaha.117.311059
Liew, Alphonsus; Vassiliou, Vassilios; Cooper, Robert; Raphael, Claire (2017). Hypertrophic Cardiomyopathy—Past, Present and Future. Journal of Clinical Medicine, 6(12), 118–
. doi:10.3390/jcm6120118
MAGNUSSON, P., GADLER, F., LIV, P., & MÖRNER, S. (2015). Hypertrophic Cardiomyopathy and Implantable Defibrillators in Sweden: Inappropriate Shocks and Complications Requiring Surgery. Journal Of Cardiovascular Electrophysiology, 26(10), 1088-1094.
doi: 10.1111/jce.12750
Barra, S., Providencia, R., Paiva, L., Heck, P., & Agarwal, S. (2014). Implantable cardioverter-defibrillators in the elderly: rationale and specific age-related considerations. Europace, 17(2), 174-186. doi: 10.1093/europace/euu296
Capucci, A., De Simone, A., Luzi, M., Calvi, V., Stabile, G., & D’Onofrio, A. et al. (2017). Economic impact of remote monitoring after implantable defibrillators implantation in heart failure patients: an analysis from the EFFECT study. EP Europace, 19(9), 1493-1499.
doi: 10.1093/europace/eux017
Geske, J., Ommen, S., & Gersh, B. (2018). Hypertrophic Cardiomyopathy. JACC: Heart Failure, 6(5), 364-375.
doi: 10.1016/j.jchf.2018.02.010
Josephson, M. (2004). Implantable Defibrillators and Sudden Cardiac Death. Circulation, 109(22), 2685–2691. doi:10.1161/01.cir.0000129322.97266.f3
Beggs, Simon A S; Jhund, Pardeep S; Jackson, Colette E; McMurray, John J V; Gardner, Roy S (2017). Non-ischaemic cardiomyopathy, sudden death and implantable defibrillators: a review and meta-analysis. Heart, (), heartjnl-2016-310850–. doi:10.1136/heartjnl-2016-310850
Parthiban, N., Esterman, A., Mahajan, R., Twomey, D., Pathak, R., & Lau, D. et al. (2015). Remote Monitoring of Implantable Cardioverter-Defibrillators. Journal Of The American College Of Cardiology, 65(24), 2591-2600.
doi: 10.1016/j.jacc.2015.04.029
Nishimura, Rick A.; Ommen, Steve R. (2007). Hypertrophic Cardiomyopathy, Sudden Death, and Implantable Cardiac Defibrillators. JAMA, 298(4), –. doi:10.1001/jama.298.4.452
All Content should be original and unpublished.
